vx 497 has been researched along with carbamates in 14 studies
| Studies (vx 497) | Trials (vx 497) | Recent Studies (post-2010) (vx 497) | Studies (carbamates) | Trials (carbamates) | Recent Studies (post-2010) (carbamates) |
|---|---|---|---|---|---|
| 25 | 3 | 7 | 13,717 | 985 | 4,744 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (92.86) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jain, J; Kwong, AD; Markland, W; McQuaid, TJ | 1 |
| Almquist, SJ; Harding, MW; Jain, J; Shlyakhter, D | 1 |
| McHutchison, JG; Shad, JA | 1 |
| Chaturvedi, PR; Decker, CJ; Faust, TJ; Heiser, AD; Ku, G; Moseley, S; Nimmesgern, E | 1 |
| Chen, P; Cheney, DL; Fleener, CA; Gu, HH; Guo, J; Hollenbaugh, DL; Iwanowicz, EJ; Murali Dhar, TG; Pitts, WJ; Rouleau, KA; Shen, Z; Townsend, RM; Watterson, SH | 1 |
| Baroudy, BM; Liu, R; Malcolm, BA; Reyes, GR; Zhou, S | 1 |
| Almquist, SJ; Ford, PJ; Germann, UA; Jain, J; Nimmesgern, E; Shlyakhter, D; Wang, Y | 1 |
| Alam, J; Cheung, RC; Ette, E; Gordon, SC; McHutchison, JG; McNair, L; Moseley, S; Pottage, JC; Shiffman, ML; Wright, TL | 1 |
| Beevers, RE; Buckley, GM; Davies, N; Fraser, JL; Galvin, FC; Hannah, DR; Haughan, AF; Jenkins, K; Mack, SR; Pitt, WR; Ratcliffe, AJ; Richard, MD; Sabin, V; Sharpe, A; Williams, SC | 1 |
| Kochling, JD; Looker, AR; Miao, H; Montgomery, ER; Shannon, M; Young, CR | 1 |
| Alam, J; Bengtsson, L; Bronowicki, JP; Garg, V; Grange, JD; Horsmans, Y; Marcellin, P; McNair, L; Nevens, F; Purdy, S; Vetter, D | 1 |
| Pockros, PJ; Shields, WW | 1 |
| Aalyson, M; Afdhal, N; Alam, J; Bengtsson, L; Bonkovsky, HL; Chandorkar, G; Gharakhanian, S; Gordon, SC; Harding, M; Kauffman, R; Lawitz, E; Lee, WM; McHutchison, JG; McNair, L; Poordad, F; Rustgi, VK | 1 |
| Bukreyeva, N; Kalkeri, R; Koma, T; Kwong, AD; Manning, JT; Paessler, S; Smith, J; Tong, X | 1 |
1 review(s) available for vx 497 and carbamates
| Article | Year |
|---|---|
Current and future therapies of hepatitis C.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Hepacivirus; Hepatitis C, Chronic; Humans; Immunization, Passive; Immunologic Factors; IMP Dehydrogenase; Interferon-alpha; Phenylurea Compounds; Ribavirin; RNA, Viral | 2001 |
3 trial(s) available for vx 497 and carbamates
| Article | Year |
|---|---|
A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; IMP Dehydrogenase; Injections, Subcutaneous; Interferon-alpha; Male; Middle Aged; Phenylurea Compounds | 2005 |
Phase 2 study of the combination of merimepodib with peginterferon-alpha2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Phenylurea Compounds; Placebos; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Double-Blind Method; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Phenylurea Compounds; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
10 other study(ies) available for vx 497 and carbamates
| Article | Year |
|---|---|
Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon.
Topics: Animals; Antiviral Agents; Carbamates; Cattle; Cell Line; Cytopathogenic Effect, Viral; Electrophoresis; Enzyme Inhibitors; Fibroblasts; Guanosine; Humans; IMP Dehydrogenase; Interferon-alpha; Mice; Molecular Weight; Phenylurea Compounds; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; Signal Transduction; Viral Plaque Assay; Virus Replication; Viruses | 2000 |
VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent.
Topics: Animals; B-Lymphocytes; Carbamates; Cell Line; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Immunosuppressive Agents; IMP Dehydrogenase; Keratinocytes; Male; Mice; Mice, Inbred C57BL; Phenylurea Compounds; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; T-Lymphocytes | 2001 |
The novel IMPDH inhibitor VX-497 prolongs skin graft survival and improves graft versus host disease in mice.
Topics: Animals; Carbamates; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Graft Rejection; Graft Survival; Graft vs Host Disease; Immunosuppressive Agents; IMP Dehydrogenase; Interferon-gamma; Mice; Mice, Inbred Strains; Models, Animal; Phenylurea Compounds; Skin; Skin Transplantation; Spleen | 2001 |
Inhibitors of inosine monophosphate dehydrogenase: SARs about the N-[3-Methoxy-4-(5-oxazolyl)phenyl moiety.
Topics: Animals; Carbamates; Cell Line; Cricetinae; Cricetulus; Enzyme Inhibitors; IMP Dehydrogenase; Inhibitory Concentration 50; Lymphocyte Activation; Mycophenolic Acid; Oxazoles; Phenylurea Compounds; Structure-Activity Relationship; T-Lymphocytes | 2003 |
The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA.
Topics: Antimetabolites; Carbamates; Cell Line, Transformed; Enzyme Inhibitors; Genome, Viral; Guanosine; Hepacivirus; Humans; IMP Dehydrogenase; Mutation; Mycophenolic Acid; Phenylurea Compounds; Replicon; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA; RNA, Viral; Transfection; Virus Replication | 2003 |
Regulation of inosine monophosphate dehydrogenase type I and type II isoforms in human lymphocytes.
Topics: Carbamates; Enzyme Inhibitors; Humans; IMP Dehydrogenase; Isoenzymes; Leukocytes, Mononuclear; Lymphocytes; Mycophenolic Acid; Phenylurea Compounds; RNA, Messenger; Tumor Cells, Cultured | 2004 |
Low molecular weight indole fragments as IMPDH inhibitors.
Topics: Carbamates; Crystallography, X-Ray; Enzyme Inhibitors; Hydrogen Bonding; IMP Dehydrogenase; Indoles; Models, Molecular; Molecular Structure; Molecular Weight; Oxazoles; Phenylurea Compounds; Sensitivity and Specificity; Structure-Activity Relationship | 2006 |
Understanding the degradation pathway of a poorly water-soluble drug formulated in PEG-400.
Topics: Capsules; Carbamates; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Drug Contamination; Hydrolysis; Mass Spectrometry; Molecular Structure; Pharmaceutical Preparations; Phenylurea Compounds; Polyethylene Glycols; Solubility; Solutions; Temperature; Time Factors; Water | 2007 |
Ribavirin analogs.
Topics: Anemia, Hemolytic; Antiviral Agents; Carbamates; Hepacivirus; Hepatitis C; Humans; IMP Dehydrogenase; Mycophenolic Acid; Phenylurea Compounds; Ribavirin | 2009 |
Merimepodib, an IMPDH inhibitor, suppresses replication of Zika virus and other emerging viral pathogens.
Topics: Animals; Antiviral Agents; Carbamates; Cell Line; Chlorocebus aethiops; Ebolavirus; Humans; IMP Dehydrogenase; Phenylurea Compounds; RNA, Viral; Vero Cells; Virus Replication; Zika Virus; Zika Virus Infection | 2018 |